Division of Gastroenterology and Hepatology, Department of Medicine, University of Missouri School of Medicine, Columbia, Missouri, USA.
Department of Medicine, University of Missouri School of Medicine, Columbia, Missouri, USA.
J Gastroenterol Hepatol. 2021 Apr;36(4):918-926. doi: 10.1111/jgh.15241. Epub 2020 Sep 15.
The coronavirus disease 2019 pandemic has engulfed the world and is the highlight of medical community at this time. As humanity fights the battle against this virus, questions are arising regarding the appropriate management of at risk patient populations. The immunocompromised cohort is particularly susceptible to this infection, and we have tried to explore the medical management of one such group, which is composed of individuals with inflammatory bowel disease (IBD). There is limited data on the management of IBD during the ongoing pandemic. Several medical societies have put forth suggestions on how to manage immunocompromised patients in order to minimize risk of developing coronavirus disease 2019. This review aims to present available recommendations from experts and provides an insight on preventive and therapeutic strategies that can be implemented for the medical management of patients with IBD. We anticipate that as more information arises, new guidelines will emerge.
2019 年冠状病毒病大流行席卷全球，是当前医学界关注的焦点。在人类与这种病毒作斗争的同时，人们开始关注高危人群的适当管理问题。免疫功能低下人群尤其容易受到这种感染，我们试图探讨其中一组人群的医学管理，即患有炎症性肠病 (IBD) 的人群。目前关于大流行期间 IBD 管理的数据有限。为了尽量降低患 2019 年冠状病毒病的风险，一些医学协会提出了关于如何管理免疫功能低下患者的建议。这篇综述旨在介绍专家提供的现有建议，并提供可用于 IBD 患者医学管理的预防和治疗策略的见解。我们预计，随着更多信息的出现，将会出现新的指南。
